Background {#Sec1}
==========

The most common malignant neoplasm in women, breast cancer has a higher developed versus developing countries. It is a complex and multi-factorial disease caused by a combination of genetic and environmental factors. Although the exact mechanism of breast cancer carcinogenesis is still not completely elucidated, many factors are known to influence its development including age, nulliparity, early menarche, late menopause, and family history \[[@CR1]\]. In addition, inherited susceptibility accounts for approximately 27% of breast cancer risk, demonstrating that genetic factors contribute to risk of developing breast cancer \[[@CR2]\].

Progesterone (PR) is known to regulate cell proliferation and differentiation in the female reproduction system \[[@CR3]\]. Dysregulated oestrogen and progesterone signaling results in disorders such as breast cancer, subfertility, endometriosis, and endometrial cancer that depend on steroid hormones \[[@CR4]\]. Negative associations between PR protein levels and pathological grade, tumor size, and axillary lymph node involvement are frequently reported \[[@CR5]--[@CR8]\]. Additionally, PR positive tumors are believed to confer a more favorable prognosis. Moreover, primary breast tumors which lack PR are more prone to develop secondary sites than tumors which express PR in those postmenopausal patients \[[@CR9]\]. This suggests that PR may also limit breast cancer progression.

The progesterone receptor (PgR) is essential for mediating the effects of progesterone, which is necessary to establish and maintain pregnancy. The PgR gene encodes two iso-forms, PR-A and PR-B. Breast cancers commonly express a predominance of one PR isoform, and the loss of coordinated expression in the ratio between PR-A/PR-B proteins within a cell is likely to result in an aberrant hormonal response \[[@CR10]\]. The PgR gene contains eight exons and seven introns (A-G), and is located on chromosome 11q22--23 \[[@CR11]\]. While associations between PgR gene polymorphisms and breast cancer have been well-studied, results remain inconsistent \[[@CR12]--[@CR15]\].

Among the variations of PgR gene, the +331G/A variant (rs10895068), locating in the promoter region, has been wildly studied. One case--control study including 990 cases and 1364 controls showed that the +331G \> A polymorphism increases PR-B isoform expression, which is reported to increase PR-B-dependent mammary cell proliferation, thereby promoting breast cancer \[[@CR16]\]. However, no association was found between +331G \> A and breast cancer risk in a recent study of postmenopausal women \[[@CR14]\]. Although a biological mechanism is plausible, the role of the +331G \> A polymorphism in breast cancer remains ambiguous. We hypothesize that conflicting results are due to the limited sample sizes as well as differing genetic backgrounds. Meta-analysis can be used as a statistical method to reconcile studies with inconsistent results \[[@CR17]\]. Therefore, we employed this method to investigate the relationship between the PrG +331G/A polymorphism and breast cancer risk.

Methods {#Sec2}
=======

Selection of eligible studies {#Sec3}
-----------------------------

We used four online electronic databases to select studies to include in this meta-analysis (PubMed, Web of Science, and Embase in English and China National Knowledge Infrastructure Database in Chinese; most recent search update, February 2017). Search terms included "breast cancer" or "breast neoplasm" or "mammary" combined with "progesterone receptor gene" or "PgR" or "+331G/A" or "+331G \> A" or "rs10895068" and with "polymorphism" or "variant" or "genotype" or "allele", without any limitation applied. Referenced lists of all included studies were then manually searched to identify any additional eligible studies. Only the study with the most recent, complete data was included when multiple studies included the same set of subjects.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Included studies met the following criteria: (1) case-control design; (2) clinical trial evaluating associations between +331G/A gene polymorphisms and breast cancer susceptibility; (3) pathological confirmation of breast cancer diagnosis was reported for all patients; (4) data regarding sample size and individual genotype frequencies were available for all cases and controls; and (5) at least two comparison groups (cancer group and control group) were included. Exclusion criteria: (1) duplication of prior studies and (2) meta-analysis, letters, reviews, or editorial articles.

Data extraction {#Sec5}
---------------

Two investigators (Xing-ling Qi and Jun Yao) independently extracted data from eligible studies. Inconsistencies were resolved via discussion between the investigators. We recorded the first author's name, publication year, country of origin, ethnicity studied, sample size, genotypes and allele frequencies for patients with the PgR +331G/A polymorphism, and Hardy-Weinberg equilibrium (HWE) results for controls groups. We recorded studies including more than one ethnicity as mixed ethnicity.

Statistical analysis {#Sec6}
--------------------

We used STATA 12.0 software (Stata Statistical software, College Station, TX, USA) to perform all statistical analysis. PRISMA checklists and guidelines were adhered to when performing the meta-analysis \[[@CR18]\]. For control groups, we used Chi-square tests to analyze the Hardy-Weinberg equilibrium (HWE), with *p* \< 0.05 indicating a significant deviation. Pooled frequency analyses were performed using Thakkinstian's method \[[@CR18], [@CR19]\]. The strength of associations between the +331G/A polymorphism and breast cancer risk were evaluated using odds ratios (ORs) and 95% confidence intervals (CIs). Two-tailed tests were used to generate all *p* values.

We used five models to evaluate associations the +331G/A and breast cancer risk: allele model, dominant model, recessive model, homozygote comparison model, and heterozygote model. A random effects model was used to pool effect sizes of all included studies for a possible effect size across populations with different genetic backgrounds after considering the heterogeneity among the included studies \[[@CR20]\]. We also used A as the risk allele to compare OR1 (AA vs. aa), OR2 (Aa vs. aa), and OR3 (AA vs. Aa) and further determined the genetic model that was the most appropriate under the instruction, as previously described \[[@CR21], [@CR22]\]. Heterogeneities among studies were estimated using an I^2^ test, and describe I^2^ values as low (25%), moderate (50%), or high (75%) estimates \[[@CR22]\]. A Z-test resulting in a *p* value less than 0.05 determined statistical significance. We also explored the effect of included studies on combined ORs via sensitivity analysis employing sequential omission of each study. In addition, we conducted subgroup analyses by ethnicity (i.e. Caucasian, Asian, and mixed races) as well as by source of control subjects (i.e. hospital-based vs. population-based). We generated a funnel plot to reflect any possible publication bias \[[@CR23], [@CR24]\], with an Egger's test resulting in a*p* \< 0.05 indicating significant publication bias.

Results {#Sec7}
=======

We performed the online search of multiple databases for available studies reporting associations between PgR +331G/A polymorphisms and breast cancer risk. We included 13 original articles in this meta-analysis after meeting inclusion criteria. As shown in Table [1](#Tab1){ref-type="table"}, the studies eventually involved 12,453 patient and 14,056 control subjects \[[@CR12], [@CR14], [@CR16], [@CR25]--[@CR33]\]. The frequencies of each genotype and allele along with their HWE values were described in Table [2](#Tab2){ref-type="table"}. All studies reported control genotype distributions in accordance with HWE, save for that of Kotsopoulos, et al. (2009) (*p* \< 0.0001) \[[@CR25]\].Table 1Baseline characteristics of qualified studies in this meta-analysisAuthorYearCountryEthnicityControls sourceMean age of control groupCases, nControls, nDe Vivo2003AmericaCaucasianhospital-based57.29901364Diergaarde2008AmericaCaucasianpopulation-based--323650Feigelson2004AmericaCaucasianpopulation-based62479494Fernandez2006SpainCaucasianpopulation-based--544553Huggins2006AmericaCaucasianhospital-based--12981728Jin2008ChinaHanpopulation-based48.67206214Johnatty2008AustraliaCaucasianpopulation-based--1443530Kotsopoulos2009AmericaCaucasianhospital-based--16642391Pearce2005AmericaCaucasianpopulation-based--16742432Pooley2006NorfolkCaucasianpopulation-based--21872269Reding2009Americamixed racepopulation-based--12641021Romano2005NetherlandsCaucasianpopulation-based64.8535379Romano2007NetherlandsCaucasianhospital-based--16931 Table 2Distribution of genotype and allele frequencies of the *PGR* + 331G/A variationGenotype distributionAllele frequencyCases, nControls, nCases, %Controls, %AuthorGGAGAAGGAGAA*P* ~HWE~GAGADe Vivo864126\*1218139\*----------Diergaarde29429\*58070\*----------Feigelson4255314454810.803994.35.794.95.1Fernandez5083605094310.926697.03.096.04.0Huggins1134164\*1560168\*----------Jin1822401991500.595294.06.096.04.0Johnatt1282161\*47456\*----------Kotsopoulos14631956217420215\<0.000194.06.095.05.0Pearce1596762231711320.608697.62.497.62.4Pooley19292535200226070.637994.06.094.06.0Reding1128161\*910111\*----------Romano47648113393730.087493.07.094.06.0Romano15315125510.278195.05.088.711.3*P* ~HWE~ the *P* value of Hardy-Weinberg equilibrium test in the genotype distribution of controls, \*For these just presenting the genotyping of AG + AA, dominant model is calculated only

Association between PgR +331G \> A and breast cancer {#Sec8}
----------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows our results generated using five genetic models to evaluate associations between the +331G \> A polymorphism and breast cancer risk. Genetic model selection principles were used to determine the dominant model. Our summary results indicate that an association is indeed present between PgR +331G \> A and the risk of breast cancer. Using a random effects model, we calculated a pooled OR of 1.140 (*p* = 0.027, 95% CI = 1.015--1.279) (Fig. [1](#Fig1){ref-type="fig"}).Table 3Summarized ORs with 95% CIs for the association between *PGR* polymorphism and breast cancerPolymorphismGenetic modelnStatistical modelOR95% CIp~z~I^2^ (%)p~h~p~e~+331G/AAllele contrast8Random1.0730.915--1.2570.38843.90.0860.871Homozygous codominant8Random0.8630.488--1.5240.61100.4790.937Heterozygous codominant8Random1.0840.908--1.2940.37448.40.060.767Dominant12Random1.1401.015--1.2790.02736.00.1030.686Recessive8Random1.0840.658--2.2770.37448.50.0590.774*n* the number of studies, *p* ~z~ *P* value for association test, *p* ~h~, *p* value for heterogeneity test, *p* ~e~ *p* value for publication bias test Fig. 1Forest plot of the association between +331G/A in the *PGR* gene and breast cancer in a dominant model (AG + AA vs. GG)

Subgroup analysis {#Sec9}
-----------------

We found no association between +331G/A polymorphism and breast cancer risk in Caucasian (*p* = 0.102, OR = 1.116, 95% CI = 0.978--1.272,), Asian (*p* = 0.105, OR = 1.749, 95% CI = 0.890--3.438) and mixed race (*p* = 0.231, OR = 1.170, 95% CI = 0.905--1.513) populations via subgroup analysis. Furthermore, using subgroup analysis by source of controls, there was an association between +331G/A locus and breast cancer risk in hospital-based (*p* = 0.004, OR = 1.295, 95% CI = 1.087--1.543,), but not in population-based controls (*p* = 0.440, OR = 1.046, 95% CI = 0.934--1.171; Table [4](#Tab4){ref-type="table"}).Table 4Stratified analysis of the association of *PGR* polymorphism with breast cancer under dominant modelSubgroup analysis+331G/AnOR95% CIp~z~I^2^ (%)p~h~Overall121.1401.015--1.2790.02736.00.103Ethnicity Caucasians101.1160.978--1.2720.10242.60.074 Han11.7490.890--3.4380.105---- mixed race11.1700.905--1.5130.231----Source of controls Population-based81.0460.934--1.1710.4400.00.586 Hospital-based41.2951.087--1.5430.00436.20.195*n* the number of studies, *p* ~z~ *p* value for association test, *p* ~h~ *p* value for heterogeneity test

Sensitivity analysis {#Sec10}
--------------------

We examined the influence of individual studies the pooled ORs for +331G/A via sensitivity analysis involving omitting each study in each genetic model; the results did not change. This indicates that our results are statistically robust for all five genetic models examining associations between +331G/A and breast cancer susceptibility.

Publication bias {#Sec11}
----------------

We assessed possible publication bias using a Begg's funnel plot and Egger's test. As shown in Fig. [2](#Fig2){ref-type="fig"}, no obvious asymmetry was observed in the funnel plot all genotypes in the overall population, and Begg's test results did not reveal any publication bias (*p* \> 0.05).Fig. 2Funnel plot for evaluation of publication bias in breast cancer

Discussion {#Sec12}
==========

This meta-analysis included 12,453 breast cancer cases and 14,056 controls, and was used to evaluate reported associations between breast cancer risk and the +331G/A (rs10895068) functional polymorphism in the PgR gene promoter. In the dominant model, when all studies meeting eligibility criteria were pooled, we found an association between +331G/A and breast cancer risk. However, after subgroup analysis, this association disappeared in Caucasians, Asian, and mixed race. Therefore, we could cautiously assert that there is no association of the +331G/A PgR gene polymorphism and breast cancer susceptibility in Caucasian and Asian populations.

There have been several prior meta-analysis studies reporting on this particular association, with mixed results. An association between breast cancer risk and PgR +331G/A was reported by Yang, et al. \[[@CR34]\]. However, the other two published meta-analyses, which each included more studies than that of Yang, et al., did not confirm this association \[[@CR35], [@CR36]\]. The present study, however, has several advantages over these prior studies. First, more recently-published studies were included in the present meta-analysis, which may underscore the reliability of our findings. Second, the present study added additional subgroup analyses by both ethnicity and sources of controls to control for heterogeneity. Third, we also included a Chinese database in our literature search to more comprehensively assess studies in Chinese populations. These advantages allowed us to more precisely assess the + 331G/A *PgR* gene polymorphism and breast cancer risk associations than previous meta-analyses.

There were several limitations to this study that may have affected our results. Firs, only 13 studies were included in our meta-analysis, which limited subsequent analyses because of a shortage of original studies. Second, there was moderate heterogeneity in the overall meta-analysis and in the subgroup analysis that suggested that ethnicity and source of controls, to some extent, contributed heterogeneity between studies. Third, other factors influencing breast cancer, such as genetic background, environment, and lifestyle factors, should also be considered. Finally, there was only ten studies that specified Caucasians and just one study that compared certain populations (Asian and mixed race) in the ethnicity sub-group analyses. Thus, the discrepancy of association among different ethnic sub-groups should be interpreted carefully.

Conclusion {#Sec13}
==========

In conclusion, our meta-analysis suggested that the +331G/A polymorphism may not be associated with susceptibility to breast cancer. However, because of the comparatively insufficient number of published studies included, our conclusions require support from additional studies. More evidence from epidemiologic studies is required to validate our results regarding the role of +331G/A (rs10895068) in the genetic susceptibility to breast cancer.
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